These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1178 related articles for article (PubMed ID: 8599114)

  • 1. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time.
    Perelson AS; Neumann AU; Markowitz M; Leonard JM; Ho DD
    Science; 1996 Mar; 271(5255):1582-6. PubMed ID: 8599114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.
    Ho DD; Neumann AU; Perelson AS; Chen W; Leonard JM; Markowitz M
    Nature; 1995 Jan; 373(6510):123-6. PubMed ID: 7816094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection.
    Markowitz M; Saag M; Powderly WG; Hurley AM; Hsu A; Valdes JM; Henry D; Sattler F; La Marca A; Leonard JM
    N Engl J Med; 1995 Dec; 333(23):1534-9. PubMed ID: 7477168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir.
    Kelleher AD; Carr A; Zaunders J; Cooper DA
    J Infect Dis; 1996 Feb; 173(2):321-9. PubMed ID: 8568292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo.
    Markowitz M; Louie M; Hurley A; Sun E; Di Mascio M; Perelson AS; Ho DD
    J Virol; 2003 Apr; 77(8):5037-8. PubMed ID: 12663814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group.
    Danner SA; Carr A; Leonard JM; Lehman LM; Gudiol F; Gonzales J; Raventos A; Rubio R; Bouza E; Pintado V
    N Engl J Med; 1995 Dec; 333(23):1528-33. PubMed ID: 7477167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viral dynamics in human immunodeficiency virus type 1 infection.
    Wei X; Ghosh SK; Taylor ME; Johnson VA; Emini EA; Deutsch P; Lifson JD; Bonhoeffer S; Nowak MA; Hahn BH
    Nature; 1995 Jan; 373(6510):117-22. PubMed ID: 7529365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of drug efficacy and the eclipse phase of the viral life cycle on estimates of HIV viral dynamic parameters.
    Nelson PW; Mittler JE; Perelson AS
    J Acquir Immune Defic Syndr; 2001 Apr; 26(5):405-12. PubMed ID: 11391159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abbott laboratories files New Drug Application for ritonavir.
    J Int Assoc Physicians AIDS Care; 1996 Jan; 2(1):35. PubMed ID: 11363329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nipping HIV in the bud.
    Smart T
    GMHC Treat Issues; 1996 Aug; 10(8):3-6. PubMed ID: 11363719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 dynamics in vivo.
    Ho DD
    J Biol Regul Homeost Agents; 1995; 9(3):76-7. PubMed ID: 8782010
    [No Abstract]   [Full Text] [Related]  

  • 12. Evidence for human immunodeficiency virus type 1 replication in vivo in CD14(+) monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy.
    Zhu T; Muthui D; Holte S; Nickle D; Feng F; Brodie S; Hwangbo Y; Mullins JI; Corey L
    J Virol; 2002 Jan; 76(2):707-16. PubMed ID: 11752161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decay characteristics of HIV-1-infected compartments during combination therapy.
    Perelson AS; Essunger P; Cao Y; Vesanen M; Hurley A; Saksela K; Markowitz M; Ho DD
    Nature; 1997 May; 387(6629):188-91. PubMed ID: 9144290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viral dynamics in vivo: limitations on estimates of intracellular delay and virus decay.
    Herz AV; Bonhoeffer S; Anderson RM; May RM; Nowak MA
    Proc Natl Acad Sci U S A; 1996 Jul; 93(14):7247-51. PubMed ID: 8692977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abbott protease inhibitor in combination: sustained viral load drop.
    AIDS Treat News; 1995 Sep; (no 231):4-5. PubMed ID: 11362868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High turnover of HIV in blood revealed by new studies.
    Cohen J
    Science; 1995 Jan; 267(5195):179. PubMed ID: 7809623
    [No Abstract]   [Full Text] [Related]  

  • 17. Results on new AIDS drugs bring cautious optimism.
    Cohen J
    Science; 1996 Feb; 271(5250):755-6. PubMed ID: 8628987
    [No Abstract]   [Full Text] [Related]  

  • 18. Estimates of intracellular delay and average drug efficacy from viral load data of HIV-infected individuals under antiretroviral therapy.
    Dixit NM; Markowitz M; Ho DD; Perelson AS
    Antivir Ther; 2004 Apr; 9(2):237-46. PubMed ID: 15134186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on HIV transmission and pathogenesis.
    Gozlan M
    Lancet; 1995 Nov; 346(8985):1290. PubMed ID: 7475727
    [No Abstract]   [Full Text] [Related]  

  • 20. Improved estimates for HIV-1 clearance rate and intracellular delay.
    Mittler JE; Markowitz M; Ho DD; Perelson AS
    AIDS; 1999 Jul; 13(11):1415-7. PubMed ID: 10449298
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 59.